<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Common terminology criteria for adverse events</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Common terminology criteria for adverse events</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Common terminology criteria for adverse events</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1156990"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The National Cancer Institute (NCI) of the National Institutes of Health (NIH) has published standardized definitions for adverse events (AEs), known as the Common Terminology Criteria for Adverse Events (CTCAE, also called "common toxicity criteria" [CTC]), to describe the severity of organ toxicity for patients receiving cancer therapy. This topic presents selected tables describing some of the AEs graded in the most recent CTCAE (version 5.0), which was published in November 2017 and became effective in April 2018 [<a href="#rid1">1</a>]; it also provides references for other adverse event reporting systems.</p><p>Additional information about specific chemotherapy and radiation therapy-associated toxicity is presented in separate topic reviews, which are mentioned under the disease-specific headings included herein.</p><p>General effects of radiation therapy and molecularly targeted agents (eg, vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors) are also discussed in separate reviews. (See  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a> and  <a class="medical medical_review" href="/d/html/7055.html" rel="external">"Clinical manifestations, prevention, and treatment of radiation-induced fibrosis"</a>.)</p><p class="headingAnchor" id="H1938950925"><span class="h1">CTCAE OVERVIEW</span><span class="headingEndMark"> — </span>CTCAE stands for Common Terminology Criteria for Adverse Events; these criteria are also called "common toxicity criteria." In CTCAE, an adverse event (AE) is defined as any abnormal clinical finding temporally associated with the use of a therapy for cancer; causality is not required. These criteria are used for the management of chemotherapy administration and dosing, and in clinical trials to provide standardization and consistency in the definition of treatment-related toxicity.</p><p>Several updates of the CTCAE have been published. There is no set schedule for the publication of updates; typically a version is available for several years and new updates are released to improve clarity, to reflect advances in scientific underpinnings, or, for version 4.0, to harmonize with the medical dictionary for regulatory activities (MeDRA) system organ class (SOC). Version 4.0 was published in 2009 and was replaced by version 5.0 (v5.0) in 2018. A comprehensive listing of the v5.0 CTCAE is available from the National Cancer Institute (NCI) on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fctep.cancer.gov%2Fprotocoldevelopment%2Felectronic_applications%2Fctc.htm&amp;token=Qmx3K8wGQQekcPXJ5bTBpcn0FinUI8F2hO4xf09x3ej52IvR7kOqJoZmhB5fqFTirIqyzRZ8XoIJamOWMskP2j70%2Fzo3pR2XSuWYQhzhZZI%3D&amp;TOPIC_ID=90856" target="_blank">Cancer Therapy Evaluation Program (CTEP)</a> website.</p><p>Changes from version 4.0 to 5.0 include some differences in the grade for certain AEs (eg, cytokine release syndrome, hyperglycemia) and/or in terminology (eg, the term "prehypertension" is no longer used). The major organ system categories are the same as in version 4.0, and many of the AE grades have not been changed.</p><p>In general, toxicity is graded as mild (Grade 1), moderate (Grade 2), severe (Grade 3), or life-threatening (Grade 4), with specific parameters according to the organ system involved. Death (Grade 5) is used for some of the criteria to denote a fatality occurring during treatment. Approximately 10 percent of the AEs in the NCI CTCAE represent clinician-reported symptoms. Versions of the CTCAE that rely on patient-reported outcomes are discussed below. (See <a class="local">'Other adverse event reporting systems'</a> below.)</p><p class="headingAnchor" id="H2916119799"><span class="h1">CTCAE CATEGORIES</span><span class="headingEndMark"> — </span>The following represents a selection of some of the adverse events (AEs) graded in the most recent CTCAE (version 5.0 [v5.0]). A comprehensive listing of the v5.0 CTCAE is available from the National Cancer Institute (NCI) on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fctep.cancer.gov%2Fprotocoldevelopment%2Felectronic_applications%2Fctc.htm&amp;token=Qmx3K8wGQQekcPXJ5bTBpcn0FinUI8F2hO4xf09x3ej52IvR7kOqJoZmhB5fqFTirIqyzRZ8XoIJamOWMskP2j70%2Fzo3pR2XSuWYQhzhZZI%3D&amp;TOPIC_ID=90856" target="_blank">Cancer Therapy Evaluation Program (CTEP)</a> website.</p><p class="headingAnchor" id="H1157011"><span class="h2">Cardiac</span><span class="headingEndMark"> — </span>Cardiac AE criteria include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure (<a class="graphic graphic_table graphicRef58345" href="/d/graphic/58345.html" rel="external">table 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Right ventricular dysfunction (<a class="graphic graphic_table graphicRef99987" href="/d/graphic/99987.html" rel="external">table 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Left ventricular systolic dysfunction (<a class="graphic graphic_table graphicRef99985" href="/d/graphic/99985.html" rel="external">table 3</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced ejection fraction (<a class="graphic graphic_table graphicRef128231" href="/d/graphic/128231.html" rel="external">table 4</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Sinus bradycardia (<a class="graphic graphic_table graphicRef91244" href="/d/graphic/91244.html" rel="external">table 5</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Prolongation of the corrected QT interval (QTc) on the electrocardiogram (<a class="graphic graphic_table graphicRef91251" href="/d/graphic/91251.html" rel="external">table 6</a>)</p><p></p><p>Cardiac toxicities of radiation and specific chemotherapeutic drugs are discussed in the following UpToDate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/774.html" rel="external">"Cardiotoxicity of trastuzumab and other HER2-targeted agents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a>.)</p><p></p><p class="headingAnchor" id="H1347752831"><span class="h2">Dermatologic</span><span class="headingEndMark"> — </span>Cutaneous complications include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Alopecia (<a class="graphic graphic_table graphicRef91256" href="/d/graphic/91256.html" rel="external">table 7</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Acneiform rash (<a class="graphic graphic_table graphicRef67786" href="/d/graphic/67786.html" rel="external">table 8</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Bullous dermatitis (<a class="graphic graphic_table graphicRef132748" href="/d/graphic/132748.html" rel="external">table 9</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperhidrosis (excessive sweating) (<a class="graphic graphic_table graphicRef115344" href="/d/graphic/115344.html" rel="external">table 10</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Maculopapular rash (<a class="graphic graphic_table graphicRef132663" href="/d/graphic/132663.html" rel="external">table 11</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Palmar-plantar erythrodysesthesia syndrome (<a class="graphic graphic_table graphicRef73474" href="/d/graphic/73474.html" rel="external">table 12</a>), which is also referred to as acral erythema or hand-foot syndrome. This table is also used for grading the severity of hand-foot skin reaction, which is seen with <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, and other agents targeting the vascular endothelial growth factor (VEGF) receptor. This syndrome has a different clinical and histologic appearance from the classic form of palmar-plantar erythrodysesthesia that is associated with conventional cytotoxic chemotherapy agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus (<a class="graphic graphic_table graphicRef132662" href="/d/graphic/132662.html" rel="external">table 13</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Radiation dermatitis (<a class="graphic graphic_table graphicRef91257" href="/d/graphic/91257.html" rel="external">table 14</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Skin hypopigmentation (<a class="graphic graphic_table graphicRef132816" href="/d/graphic/132816.html" rel="external">table 15</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Stevens-Johnson syndrome (<a class="graphic graphic_table graphicRef132750" href="/d/graphic/132750.html" rel="external">table 16</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Toxic epidermal necrolysis (<a class="graphic graphic_table graphicRef133281" href="/d/graphic/133281.html" rel="external">table 17</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Other skin and subcutaneous disorders (<a class="graphic graphic_table graphicRef131021" href="/d/graphic/131021.html" rel="external">table 18</a>)</p><p></p><p>Further discussions of chemotherapy-associated alopecia and cutaneous toxicity, as well as radiation-related dermatitis, are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1156.html" rel="external">"Alopecia related to systemic cancer therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7053.html" rel="external">"Acute complications of cranial irradiation", section on 'Alopecia and radiation dermatitis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13668.html" rel="external">"Radiation dermatitis"</a>.)</p><p></p><p class="headingAnchor" id="H1157004"><span class="h2">Gastrointestinal</span><span class="headingEndMark"> — </span>Gastrointestinal AE criteria include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Oral mucositis (<a class="graphic graphic_table graphicRef60597" href="/d/graphic/60597.html" rel="external">table 19</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea and vomiting (<a class="graphic graphic_table graphicRef69015" href="/d/graphic/69015.html" rel="external">table 20</a>); these are graded separately in CTCAE v5.0</p><p class="bulletIndent1"><span class="glyph">●</span>Dysphagia (<a class="graphic graphic_table graphicRef91245" href="/d/graphic/91245.html" rel="external">table 21</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Esophageal stenosis (<a class="graphic graphic_table graphicRef93931" href="/d/graphic/93931.html" rel="external">table 22</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Esophagitis (<a class="graphic graphic_table graphicRef117322" href="/d/graphic/117322.html" rel="external">table 23</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Gastroparesis (<a class="graphic graphic_table graphicRef91247" href="/d/graphic/91247.html" rel="external">table 24</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Constipation (<a class="graphic graphic_table graphicRef117320" href="/d/graphic/117320.html" rel="external">table 25</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Diarrhea (<a class="graphic graphic_table graphicRef65649" href="/d/graphic/65649.html" rel="external">table 26</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Enterocolitis (<a class="graphic graphic_table graphicRef138439" href="/d/graphic/138439.html" rel="external">table 27</a>)</p><p></p><p>Oral toxicity, treatment-related nausea and vomiting, gastroparesis, and enterotoxicity are also discussed in separate UpToDate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1152.html" rel="external">"Oral toxicity associated with systemic anticancer therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1150.html" rel="external">"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7052.html" rel="external">"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/98342.html" rel="external">"Management of acute chemotherapy-related diarrhea"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7054.html" rel="external">"Overview of gastrointestinal toxicity of radiation therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/138429.html" rel="external">"Immune checkpoint inhibitor colitis"</a>.)</p><p></p><p class="headingAnchor" id="H2722242579"><span class="h2">General and systemic</span></p><p class="headingAnchor" id="H2411734835"><span class="h3">Capillary leak syndrome</span><span class="headingEndMark"> — </span>Capillary leak syndrome can cause leakage of intravascular fluid into any extravascular space. It can lead to generalized edema, pulmonary edema, and multiorgan failure (<a class="graphic graphic_table graphicRef119056" href="/d/graphic/119056.html" rel="external">table 28</a>).</p><p class="headingAnchor" id="H1064453918"><span class="h3">Fatigue</span><span class="headingEndMark"> — </span>Fatigue is graded according to its impact on activities of daily living (<a class="graphic graphic_table graphicRef60072" href="/d/graphic/60072.html" rel="external">table 29</a>).</p><p>Performance status (PS) is not graded in the CTCAE. PS can be classified using the Karnofsky or the Eastern Cooperative Oncology Group (ECOG) scale (<a class="graphic graphic_table graphicRef57945" href="/d/graphic/57945.html" rel="external">table 30</a>).</p><p class="headingAnchor" id="H1966314268"><span class="h3">Hypertension and hypotension</span></p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension (<a class="graphic graphic_table graphicRef69770" href="/d/graphic/69770.html" rel="external">table 31</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension (<a class="graphic graphic_table graphicRef87347" href="/d/graphic/87347.html" rel="external">table 32</a>)</p><p></p><p class="headingAnchor" id="H6532839"><span class="h3">Immune system, infusion reactions, and extravasation</span><span class="headingEndMark"> — </span>Immune reactions include cytokine release syndrome (CRS) (<a class="graphic graphic_table graphicRef114251" href="/d/graphic/114251.html" rel="external">table 33</a>), serum sickness (<a class="graphic graphic_table graphicRef117356" href="/d/graphic/117356.html" rel="external">table 34</a>), and allergic and anaphylactic reactions (<a class="graphic graphic_table graphicRef91249" href="/d/graphic/91249.html" rel="external">table 35</a>). If an allergic reaction is related to a drug infusion, the grading schema for infusion-related reactions should be used.</p><p>Complications of drug infusions include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Infusion-related reactions (<a class="graphic graphic_table graphicRef57843" href="/d/graphic/57843.html" rel="external">table 36</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Injection site reactions (<a class="graphic graphic_table graphicRef114224" href="/d/graphic/114224.html" rel="external">table 37</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Infusion site extravasation (<a class="graphic graphic_table graphicRef91248" href="/d/graphic/91248.html" rel="external">table 38</a>)</p><p></p><p>These are generally graded according to the degree of intervention needed.</p><p>Management of these complications are discussed separately in UpToDate:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2835.html" rel="external">"Infusion reactions to systemic chemotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2797.html" rel="external">"Extravasation injury from cytotoxic and other noncytotoxic vesicants in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3970.html" rel="external">"Overview of therapeutic monoclonal antibodies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/118012.html" rel="external">"Cytokine release syndrome (CRS)"</a>.)</p><p></p><p class="headingAnchor" id="H3933222408"><span class="h3">Pain</span><span class="headingEndMark"> — </span>Pain is graded by severity and effect on activities of daily living. Separate criteria are used to grade pain in different locations in the body; these should be consulted for specific grading of pain [<a href="#rid1">1</a>]. The table (<a class="graphic graphic_table graphicRef58287" href="/d/graphic/58287.html" rel="external">table 39</a>) summarizes some of the common features of pain grading. (See  <a class="medical medical_review" href="/d/html/2795.html" rel="external">"Assessment of cancer pain"</a>.)</p><p class="headingAnchor" id="H3905313712"><span class="h3">Weight loss</span><span class="headingEndMark"> — </span>Weight loss is graded according to the percent decrease from the individual's baseline and the need for tube feedings or <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> (<a class="graphic graphic_table graphicRef99037" href="/d/graphic/99037.html" rel="external">table 40</a>).</p><p class="headingAnchor" id="H2943254347"><span class="h2">Hematologic</span><span class="headingEndMark"> — </span>Hematologic AE criteria include decreases in neutrophil, platelet, hemoglobin, and lymphocyte (including CD4 cell) counts (<a class="graphic graphic_table graphicRef64984" href="/d/graphic/64984.html" rel="external">table 41</a>). In v5.0, most of these were moved to the "Investigations" category, which includes many types of laboratory values, imaging, and changes in measured parameters such as urine output or weight.</p><p>Hematologic consequences of cancer therapy are also discussed separately in UpToDate:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7140.html" rel="external">"Causes of anemia in patients with cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16888.html" rel="external">"Risk assessment of adults with chemotherapy-induced neutropenia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16889.html" rel="external">"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation"</a>.)</p><p></p><p>The grading scheme for febrile neutropenia remains in the section on blood and lymphatic system disorders. Febrile neutropenia only has definitions for grades 3 through 5 toxicity (<a class="graphic graphic_table graphicRef64984" href="/d/graphic/64984.html" rel="external">table 41</a>). All patients with fever in the setting of chemotherapy-induced neutropenia require immediate medical attention regardless of the toxicity grade, as discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a> and  <a class="medical medical_review" href="/d/html/6051.html" rel="external">"Fever in children with chemotherapy-induced neutropenia"</a> and  <a class="medical medical_review" href="/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever"</a>.)</p><p>Thromboembolic events are also graded:</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial thromboembolism (<a class="graphic graphic_table graphicRef117315" href="/d/graphic/117315.html" rel="external">table 42</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Venous thromboembolism (<a class="graphic graphic_table graphicRef87383" href="/d/graphic/87383.html" rel="external">table 43</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Superior vena cava syndrome (<a class="graphic graphic_table graphicRef117316" href="/d/graphic/117316.html" rel="external">table 44</a>)</p><p></p><p>Thrombotic microangiopathies (TMAs) are separated into thrombotic thrombocytopenic purpura (TTP) (<a class="graphic graphic_table graphicRef117317" href="/d/graphic/117317.html" rel="external">table 45</a>) and hemolytic uremic syndrome (HUS) (<a class="graphic graphic_table graphicRef117318" href="/d/graphic/117318.html" rel="external">table 46</a>). Separate discussions in UpToDate discuss differences among these and other TMAs. (See  <a class="medical medical_review" href="/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a> and  <a class="medical medical_review" href="/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.)</p><p>Prevention and treatment of thromboembolic disease in patients with cancer is discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1352.html" rel="external">"Risk and prevention of venous thromboembolism in adults with cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6236.html" rel="external">"Thromboembolism in children with cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a>.)</p><p></p><p class="headingAnchor" id="H1217790735"><span class="h2">Hepatobiliary</span><span class="headingEndMark"> — </span>Hepatobiliary toxicity includes hepatic failure, portal hypertension, and laboratory evidence of liver dysfunction (<a class="graphic graphic_table graphicRef77533" href="/d/graphic/77533.html" rel="external">table 47</a>). In CTCAE v5.0, the laboratory findings of liver toxicity are graded separately under investigations. Portal hypertension and hepatic failure are classified under hepatobiliary disorders.</p><p>The term drug-induced liver injury (DILI), which is used to assign Grade 3 hepatic failure, is defined by Hy's law (ie, the drug causes hepatocellular injury, often transaminase elevations are much greater than three times the upper limit of normal, and no other reason can be found to explain the increased transaminases and total bilirubin) [<a href="#rid2">2</a>]. </p><p>Hepatotoxicity from immune checkpoint inhibitors and hepatoxicity from chemotherapy or molecularly targeted agents in patients with underlying liver disease are discussed separately. (See  <a class="medical medical_review" href="/d/html/134862.html" rel="external">"Hepatic, pancreatic, and rare gastrointestinal complications of immune checkpoint inhibitor therapy", section on 'Hepatotoxicity'</a> and  <a class="medical medical_review" href="/d/html/2837.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents"</a> and  <a class="medical medical_review" href="/d/html/128144.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents"</a>.)</p><p class="headingAnchor" id="H1157317"><span class="h2">Kidney and urinary tract</span><span class="headingEndMark"> — </span>Acute kidney injury is graded clinically (ie, whether hospitalization or dialysis is indicated); increased creatinine is graded separately and classified under "Investigations" (<a class="graphic graphic_table graphicRef91253" href="/d/graphic/91253.html" rel="external">table 48</a>).</p><p>Proteinuria (<a class="graphic graphic_table graphicRef91255" href="/d/graphic/91255.html" rel="external">table 49</a>) and cystitis (<a class="graphic graphic_table graphicRef91254" href="/d/graphic/91254.html" rel="external">table 50</a>) are also graded.</p><p>Chronic kidney disease is also graded; however, experts prefer to classify chronic kidney disease according to published guidelines from expert groups such as the Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease Improving Global Outcomes (KDIGO) [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/16406.html" rel="external">"Definition and staging of chronic kidney disease in adults", section on 'Definition and staging of chronic kidney disease'</a>.)</p><p>Further discussions of chemotherapy-induced nephrotoxicity and cystitis related to cancer therapy are presented separately. (See  <a class="medical medical_review" href="/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents"</a> and  <a class="medical medical_review" href="/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy"</a> and  <a class="medical medical_review" href="/d/html/2829.html" rel="external">"Chemotherapy and radiation-related hemorrhagic cystitis in cancer patients"</a>.)</p><p class="headingAnchor" id="H1157626"><span class="h2">Lung</span><span class="headingEndMark"> — </span>Pulmonary AE criteria include:</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea (<a class="graphic graphic_table graphicRef117321" href="/d/graphic/117321.html" rel="external">table 51</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumonitis (<a class="graphic graphic_table graphicRef61493" href="/d/graphic/61493.html" rel="external">table 52</a>)</p><p></p><p>Pulmonary toxicity of chemotherapeutic, molecularly targeted agents, and radiation-related lung injury are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4315.html" rel="external">"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4336.html" rel="external">"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4327.html" rel="external">"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4331.html" rel="external">"Radiation-induced lung injury"</a>.)</p><p></p><p class="headingAnchor" id="H3728182"><span class="h2">Metabolism and fluid balance</span><span class="headingEndMark"> — </span>Electrolyte abnormalities related to cancer therapy include hyper- and hyponatremia, hyper- and hypokalemia, hyper- and hypocalcemia, hyper- and hypomagnesemia, hyperuricemia, and hypophosphatemia (<a class="graphic graphic_table graphicRef91252" href="/d/graphic/91252.html" rel="external">table 53</a>). These are all graded separately under "Investigations."</p><p>Hyperglycemia and hypoglycemia are also graded (<a class="graphic graphic_table graphicRef91272" href="/d/graphic/91272.html" rel="external">table 54</a>), as is dehydration (<a class="graphic graphic_table graphicRef111516" href="/d/graphic/111516.html" rel="external">table 55</a>).</p><p class="headingAnchor" id="H832267421"><span class="h2">Musculoskeletal and connective tissue disorders</span><span class="headingEndMark"> — </span>Osteonecrosis of the jaw is graded (<a class="graphic graphic_table graphicRef121995" href="/d/graphic/121995.html" rel="external">table 56</a>). </p><p class="headingAnchor" id="H1157725"><span class="h2">Neurologic and psychiatric</span><span class="headingEndMark"> — </span>Neurologic disorders include paresthesias and motor and sensory neurotoxicity (<a class="graphic graphic_table graphicRef78736" href="/d/graphic/78736.html" rel="external">table 57</a>). </p><p>Specific cranial neuropathies are graded (eg, oculomotor nerve (<a class="graphic graphic_table graphicRef117357" href="/d/graphic/117357.html" rel="external">table 58</a>)). Hearing impairment is graded separately (<a class="graphic graphic_table graphicRef117341" href="/d/graphic/117341.html" rel="external">table 59</a>) and not considered to be an impairment of the vestibulocochlear nerve.</p><p>Agitation, confusion, and delirium are graded as psychiatric disorders (<a class="graphic graphic_table graphicRef91811" href="/d/graphic/91811.html" rel="external">table 60</a>).</p><p>Neurologic complications of chemotherapy and radiation therapy are also discussed separately in UpToDate:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2826.html" rel="external">"Overview of neurologic complications of platinum-based chemotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7053.html" rel="external">"Acute complications of cranial irradiation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7066.html" rel="external">"Complications of spinal cord irradiation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5266.html" rel="external">"Brachial plexus syndromes", section on 'Neoplastic and radiation-induced brachial plexopathy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5267.html" rel="external">"Lumbosacral plexus syndromes", section on 'Radiation plexopathy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/94976.html" rel="external">"Prevention and treatment of chemotherapy-induced peripheral neuropathy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/129618.html" rel="external">"Immune effector cell-associated neurotoxicity syndrome (ICANS)"</a>.)</p><p></p><p class="headingAnchor" id="H1708902733"><span class="h2">Ocular</span><span class="headingEndMark"> — </span>Ocular complications include inflammatory conditions such as uveitis (<a class="graphic graphic_table graphicRef118296" href="/d/graphic/118296.html" rel="external">table 61</a>) as well as disorders that affect vision and those that cause other ocular symptoms. (See  <a class="medical medical_review" href="/d/html/96203.html" rel="external">"Ocular side effects of systemically administered chemotherapy"</a>.)</p><p class="headingAnchor" id="H898017791"><span class="h1">OTHER ADVERSE EVENT REPORTING SYSTEMS</span><span class="headingEndMark"> — </span>Patient-Reported Outcomes (PRO) take into account the patient's perspective on adverse events (AEs), which may be under-detected using the existing CTCAE system [<a href="#rid4">4</a>]. A PRO version of the National Cancer Institute (NCI) CTCAE (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fhealthcaredelivery.cancer.gov%2Fpro-ctcae%2Finstrument.html&amp;token=%2BabCEL7dMnUHQESl8Z63%2FHAcdI8HT%2Bhbs3xauHPV6obXQHW3xbiBtpAD7Nj0BLwm2vRTTmXWei%2Ftvp26ze9GuOj7Hz2vClRwpdHNLeDjZuo%3D&amp;TOPIC_ID=90856" target="_blank">PRO-CTCAE</a>) has been developed and validated but is not yet in widespread use [<a href="#rid4">4-6</a>]. A systematic review of reports that compared CTCAE and PRO ratings using various PRO measures of AEs found fair to moderate agreement between the two systems, with large variations in many of the studies [<a href="#rid7">7</a>]. Translations of this document are available in other languages including German, Spanish, Danish, Japanese, and Korean [<a href="#rid8">8-12</a>].</p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-brief-fda-provides-guidance-measuring-patient-reported-outcomes-cancer-clinical-trials&amp;token=x%2FMoAD871h7ydMYJNMZKPbyq527dSBjyNSIh7P0WisAzd0kY2HILzJ45ZsnI6HuRuusLJDZw3cIQxiTbz0U1FGNjFv2ciEcZoLokWPIzGl%2BK5mCqlPd5y37CYPHFltjfWpjlXcpE1le6ApSEw6tcDQ%3D%3D&amp;TOPIC_ID=90856" target="_blank">US FDA has issued some preliminary guidelines</a>, which, when finalized, will provide recommendations on which PROs are appropriate to measure in cancer clinical trials. </p><p>For some toxicities related to radiation therapy, alternative grading criteria are available from the Radiation Therapy Oncology Group (RTOG) [<a href="#rid13">13</a>]. However, the NCI CTCAE criteria are also relevant to grading the severity of radiation therapy-related toxicity. (See  <a class="medical medical_review" href="/d/html/7058.html" rel="external">"Radiation proctitis: Clinical manifestations, diagnosis, and management", section on 'Management'</a>.)</p><p class="headingAnchor" id="H1157547"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – This topic review presents tables of some of the toxicities graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 (v5.0), which was released in November 2017 and is effective as of April 1, 2018. (See <a class="local">'CTCAE overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selected CTCAE tables</strong> – Selected tables for CTCAE categories are provided in the sections above (see <a class="local">'CTCAE categories'</a> above). A comprehensive listing of the criteria is available from the NCI on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fctep.cancer.gov%2Fprotocoldevelopment%2Felectronic_applications%2Fctc.htm&amp;token=Qmx3K8wGQQekcPXJ5bTBpcn0FinUI8F2hO4xf09x3ej52IvR7kOqJoZmhB5fqFTirIqyzRZ8XoIJamOWMskP2j70%2Fzo3pR2XSuWYQhzhZZI%3D&amp;TOPIC_ID=90856" target="_blank">Cancer Therapy Evaluation Program (CTEP)</a> website.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other adverse event reporting systems</strong> – References and links for other adverse event reporting systems such as the patient-reported outcomes (PRO-CTCAE) and criteria from the Radiation Therapy Oncology Group (RTOG) are listed above. (See <a class="local">'Other adverse event reporting systems'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on March 09, 2018).</li><li class="breakAll">https://www.fda.gov/downloads/Guidances/UCM174090.pdf (Accessed on March 28, 2018).</li><li><a class="nounderline abstract_t">Launay-Vacher V. Cancer and the kidney: individualizing dosage according to renal function. Ann Oncol 2013; 24:2713.</a></li><li><a class="nounderline abstract_t">Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014; 106.</a></li><li><a class="nounderline abstract_t">Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 2015; 1:1051.</a></li><li><a class="nounderline abstract_t">Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book 2016; 35:67.</a></li><li><a class="nounderline abstract_t">Atkinson TM, Ryan SJ, Bennett AV, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer 2016; 24:3669.</a></li><li><a class="nounderline abstract_t">Arnold B, Mitchell SA, Lent L, et al. Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Support Care Cancer 2016; 24:2843.</a></li><li><a class="nounderline abstract_t">Bæksted C, Nissen A, Pappot H, et al. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Pain Symptom Manage 2016; 52:292.</a></li><li><a class="nounderline abstract_t">Hagelstein V, Ortland I, Wilmer A, et al. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™). Ann Oncol 2016; 27:2294.</a></li><li><a class="nounderline abstract_t">Cho J, Yoon J, Kim Y, et al. Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean. J Glob Oncol 2019; 5:1.</a></li><li><a class="nounderline abstract_t">Miyaji T, Iioka Y, Kuroda Y, et al. Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Patient Rep Outcomes 2017; 1:8.</a></li><li><a class="nounderline abstract_t">Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31:1341.</a></li></ol></div><div id="topicVersionRevision">Topic 90856 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on March 09, 2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.fda.gov/downloads/Guidances/UCM174090.pdf" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : https://www.fda.gov/downloads/Guidances/UCM174090.pdf (Accessed on March 28, 2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24170609" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cancer and the kidney: individualizing dosage according to renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25265940" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26270597" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27249687" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27260018" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26838022" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27090851" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27681863" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30917069" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29757296" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7713792" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
